By STEVEN ZECOLA
Introduction.
The scientists at the Department of Health and Human Services (“HHS”) are breathing a sigh of relief given that the Democrats will be taking control of the House and Senate. For the past two years, there has been a tension within HHS between the scientific community and President Trump’s executive appointments. While Trump’s people have been “winning” the political battles over vaccines and restrictions on abortion-related treatments, they have not made much progress on modernizing the drug approval process, despite repeated promises. The approval process for promising therapies remains slow, uncertain, and resistant to change.
Managing by Press Release
Over the past year, HHS and FDA have announced initiatives involving personalized gene therapies, rare-disease development, AI-enabled healthcare, real-time clinical trials, and regulatory modernization.
Collectively, these announcements convey an agency committed to accelerating innovation. The more important issue for the public is whether these initiatives are changing how therapies move through the approval process.
From Promises to Practice
To judge whether reform is occurring, it is necessary to examine actual regulatory outcomes rather than public statements.
First, the FDA has had data for over a year showing how an innovative therapy for familial adenomatous polyposis (FAP) improves patient outcomes with minimum risk.
FAP is a genetic disorder that predisposes people to develop precancerous colon polyps. With FAP, patients will develop many colon polyps — typically over a hundred — starting at a young age. This significantly raises the lifetime risk that one of them will become cancerous. To manage this risk, healthcare providers usually recommend complete removal of the colon and sometimes the rectum, as well.
Treating FAP is an expensive, lifelong endeavor for the 50,000+ survivors. The patients are subject to repeated colonoscopies. There are no treatments for FAP other than surgery.
Early detection strategies cost $10k+ and late detection $37k+. The cost of treating metastatic colorectal cancer (for which FAP predisposes) can be extremely high, up to $300,000. Overall, the cost to society from FAP exceeds $1 billion per year.
Recursion Pharmaceuticals has utilized artificial intelligence (“AI”) to derive a treatment labelled REC-4881. It is the AI-discovery that is furthest along in the regulatory process. The FDA’s actions, or lack thereof, will redound to the benefit (or cost) of all AI healthcare entrants as well as the public.
Meanwhile, the Company recently posted Phase II results which exceed the findings of Phase 1.
As explained by the Company:
“Deep reductions sustained of treatment: In an expanded adult population aged 18 years and older, after 12 weeks of treatment, patients achieved a 47% median reduction in total polyp burden, with approximately 1 in 3 achieving reductions of ≥65%. Twelve weeks after stopping treatment, 85% of evaluable patients remained below baseline”.
As for safety, the Company reported:
“No new safety signals observed: Favorable chronic dosing safety profile, consistent with the MEK inhibitor class. The highest-grade treatment-related adverse event (TRAE) was Grade 1 or 2 in 21 of 26 patients (81%) and Grade 3 in four patients (15%); one patient experienced no TRAEs. No Grade 4 or 5 TRAEs were reported. No additional discontinuations were reported since the previous data cutoff”.
Yet, the impact of the FDA staff can be seen from the following quote:
“The Company anticipates initiating a registrational trial in the second half of 2027, pending ongoing FDA discussions, and will provide additional details later this year”.
Taking a step back, why would anyone want to delay the introduction of this treatment to these patients for several more years given the results to date? Who is the FDA protecting?
As an AI-initiated treatment, REC-4881 has the ability to collect more data, more quickly, and more accurately than for non-AI therapies. Therefore, it offers patients greater safety outcomes than traditionally provided by the FDA processes.
There are 50,000 patients waiting for either grim news, or preferably a viable treatment. Why can’t the FDA let patients decide whether they want to take a REC-4881 pill or undertake another colonoscopy (or worse).
Second, a similar pattern can be seen in HHS’s response to Parkinson’s disease. PD affects over 1 million people in the US and adds about $80 billion a year in costs to society. Congress had grown tired of decades of research with no treatment to slow, stop or cure the disease. It overwhelmingly passed legislation for HHS, with the help of an Advisory Council, to find a cure for the disease within 10 years.
What has happened? It took the staff two years to organize the first meeting of the Advisory Council. As part of its role, the staff then developed a timeline that resulted in a report being provided to Congress three and a half years after Congress had passed legislation.
In briefing the Advisory Council, the staff failed to include any mention of AI or the FDA’s protracted regulatory review process. Yet, to achieve the objective of finding a cure within 10 years, new technologies and a revised regulatory framework will be required.
The issue regarding the FDA goes beyond regulatory delay. The FDA lacks any sense of urgency – even in the face of a Congressional mandate.
Conclusion.
The debate over healthcare reform often focuses on funding levels, insurance coverage, and standards of care. Yet an equally important factor receives far less attention: the speed at which the regulatory system adapts to, or impedes, scientific innovation.
HHS leadership has repeatedly acknowledged the need for modernization. The challenge is converting those aspirations into measurable changes in how therapies are evaluated and approved. Cases such as REC-4881 and the federal Parkinson’s initiative suggest that the FDA’s regulatory intransigence is institutional in nature.
The outcome of the mid-term elections will alter the political balance in Washington, but it will not by itself change the culture, incentives, or procedures that govern the federal healthcare bureaucracy. If Congress is serious about accelerating innovation and reducing the long-term costs of chronic disease, regulatory modernization must move from press releases to practice.
Steven Zecola is a patient advocate.

3 hours ago
7

Bengali (Bangladesh) ·
English (United States) ·